Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]
Discontinued
Reference number: GID-TA10926
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early July 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early September 2024.